Education
About Us
Working with TipRanks
Follow Us
Curis Inc (CRIS)
NASDAQ:CRIS
CRIS Analyst Ratings
Moderate Buy
2 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CRIS Stock 12 Month Forecast
Average Price Target
$10.17
▲(455.74% Upside)
| Highest Price Target$17.00 | Average Price Target$10.17 | Lowest Price Target$1.50 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TR | OpenAI - 4o
$1.5
Hold
-18.03%
Downside
Reiterated
08/11/25
JonesTrading
$12
Buy
555.74%
Upside
Reiterated
08/08/25
H.C. Wainwright
$17
Buy
828.96%
Upside
Reiterated
08/05/25
Curis Inc: Promising Financial Performance and Clinical Advancements Justify Buy RatingValuation and Risks. We reiterate our Buy rating and $17 price target. Our price target is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug's profile. Our valuation is based on Curis' lead asset emavusertib for NHL and AML in the U.S. only (67% contribution; 25 % PoS), respectively. Our model also incorporates another layer of conservatism as it relates to projected annual increases to YoY market penetrance and projected annual cost of emavusertib. The overall assumptions are located in our clinical NPV model table below.
Truist Financial
―
Buy
―
Reiterated
05/07/25
Unknown Analyst
Raymond JamesNot Ranked
Raymond James
―
Hold
―
Reiterated
03/31/25
we maintain our Market Perform rating.
Laidlaw
$20
Buy
992.90%
Upside
Reiterated
09/27/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TR | OpenAI - 4o
$1.5
Hold
-18.03%
Downside
Reiterated
08/11/25
JonesTrading
$12
Buy
555.74%
Upside
Reiterated
08/08/25
H.C. Wainwright
$17
Buy
828.96%
Upside
Reiterated
08/05/25
Curis Inc: Promising Financial Performance and Clinical Advancements Justify Buy RatingValuation and Risks. We reiterate our Buy rating and $17 price target. Our price target is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug's profile. Our valuation is based on Curis' lead asset emavusertib for NHL and AML in the U.S. only (67% contribution; 25 % PoS), respectively. Our model also incorporates another layer of conservatism as it relates to projected annual increases to YoY market penetrance and projected annual cost of emavusertib. The overall assumptions are located in our clinical NPV model table below.
Truist Financial
―
Buy
―
Reiterated
05/07/25
Unknown Analyst
Raymond JamesNot Ranked
Raymond James
―
Hold
―
Reiterated
03/31/25
we maintain our Market Perform rating.
Laidlaw
$20
Buy
992.90%
Upside
Reiterated
09/27/24
Best Analysts Covering Curis
1 Month
xxx
Success Rate
13/26 ratings generated profit
Average Return
+3.27%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +3.27% per trade.
3 Months
xxx
Success Rate
7/26 ratings generated profit
Average Return
-14.76%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 26.92% of your transactions generating a profit, with an average return of -14.76% per trade.
1 Year
Success Rate
3/26 ratings generated profit
Average Return
-49.68%
reiterated a buy rating 9 days ago
Copying Soumit Roy's trades and holding each position for 1 Year would result in 11.54% of your transactions generating a profit, with an average return of -49.68% per trade.
2 Years
xxx
Success Rate
2/26 ratings generated profit
Average Return
-65.48%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 7.69% of your transactions generating a profit, with an average return of -65.48% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
CRIS Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
3
5
6
3
3
Buy
1
2
2
1
0
Hold
4
8
9
10
6
Sell
2
2
2
2
2
Strong Sell
0
0
0
0
0
total
10
17
19
16
11
Each month's total comprises the sum of three months' worth of ratings.
CRIS Financial Forecast
CRIS Stock Forecast FAQ
What is CRIS’s average 12-month price target, according to analysts?
Based on analyst ratings, Curis Inc’s 12-month average price target is 10.17.
What is CRIS’s upside potential, based on the analysts’ average price target?
Curis Inc has 455.74% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CRIS a Buy, Sell or Hold?
Curis Inc has a consensus rating of Moderate Buy which is based on 2 buy ratings, 1 hold ratings and 0 sell ratings.
What is Curis Inc’s price target?
The average price target for Curis Inc is 10.17. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $17.00 ,the lowest forecast is $1.50. The average price target represents 455.74% Increase from the current price of $1.83.
The highest analyst price target is $17.00 ,the lowest forecast is $1.50. The average price target represents 455.74% Increase from the current price of $1.83.
What do analysts say about Curis Inc?
Curis Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
How can I buy shares of CRIS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.